Industry Briefs: June 4, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: June 4, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI Burlington has been contracted as an aseptic fill manufacturer for the market introduction of Cardium Therapeutics’s and its subsidiary, Tissue Repair Company’s, wound-care product Excellagen. Read More

Baxter International has entered into an agreement with Chatham Therapeutics for development and commercialization of Chatham’s Factor IX hemophilia B gene-therapy treatment. Read More

Bayer HealthCare has formed a partnership with Covance for clinical drug development, including R&D services related to Phase II–IV clinical studies and central laboratory services. Read More

Bristol-Myers Squibb has partnered with 10 cancer-research centers in immuno-oncology. Read More

Catalent Pharma Solutions has signed a definitive agreement to sell its US commercial-packaging operations based in Philadelphia, Pennsylvania, and Woodstock, Illinois, to a company affiliated with Frazier Healthcare. The transaction is subject to certain closing conditions and is expected to close in the next few months. Read More

Forest Laboratories and Nabriva Therapeutics have entered into a $25-million agreement for the development of Nabriva’s novel antibacterial agent, BC-3781. Read More

Genmab and Novartis have agreed to use Genmab’s DuoBody technology platform to create and develop bispecific antibodies. Read More

JHP Pharmaceuticals has entered into an agreement with an undisclosed pharmaceutical company to produce the clinical and commercial supply of an innovative injectable used in the cardiovascular setting. Read More

Mylan has received FDA approval to launch a generic version of Pfizer’s Lipitor (atorvastatin calcium). Read More

WuXi PharmTech has commented on the conviction of a former employee for the theft of Merck compounds. Read More

People News

BioStorage Technologies has appointed Kristina Robson as senior director of comprehensive solutions. Read More

William G. Kaelin, Jr. has been elected to Eli Lilly's board of directors. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here